|
HER2-Positive Disease: Select publications |
Adams GP, Weiner LM. Monoclonal antibody
therapy of cancer. Nat Biotechnol 2005;23(9):1147-
57. Abstract
Altundag K et al. Adjuvant trastuzumab use in
high-risk breast cancer patients may prevent
development of contralateral estrogen receptornegative
breast tumors. Med Hypotheses 2005 Jul
22;[Epub ahead of print] No abstract available
Altundag K et al. Monoclonal antibody-based
targeted therapy in breast cancer. Curr Med
Chem Anti-Canc Agents 2005;5(2):99-106.
Abstract
Ariga R et al. Correlation of her-2/neu gene
amplification with other prognostic and predictive factors in female breast carcinoma. Breast J 2005;11(4):278-80. Abstract
Bartlett JM. Pharmacodiagnostic testing in
breast cancer: Focus on HER2 and trastuzumab
therapy. Am J Pharmacogenomics 2005;5(5):303-
15. Abstract
Baselga J et al. Phase II study of efficacy,
safety, and pharmacokinetics of trastuzumab
monotherapy administered on a 3-weekly
schedule. J Clin Oncol 2005;23(10):2162-71.
Abstract
Benohr P et al. Her-2/neu expression in breast
cancer — A comparison of different diagnostic
methods. Anticancer Res 2005;25(3B):1895-900.
Abstract
Buzdar AU et al. Significantly higher pathologic
complete remission rate after neoadjuvant
therapy with trastuzumab, paclitaxel, and
epirubicin chemotherapy: Results of a randomized
trial in human epidermal growth factor
receptor 2-positive operable breast cancer. J Clin Oncol 2005;23(16):3676-85. Abstract
De Laurentiis M et al. Targeting HER2 as
a therapeutic strategy for breast cancer: A
paradigmatic shift of drug development in
oncology. Ann Oncol 2005;16(Suppl 4):iv7-iv13.
Abstract
Del Mastro L et al. HER2 expression and efficacy
of dose-dense anthracycline-containing adjuvant
chemotherapy in breast cancer patients. Br J
Cancer 2005;93(1):7-14. Abstract
DiGiovanna MP et al. Relationship of epidermal
growth factor receptor expression to ErbB-
2 signaling activity and prognosis in breast
cancer patients. J Clin Oncol 2005;23(6):1152-60.
Abstract
Dobson R. Trastuzumab halves risk of recurrence
of breast cancer in some women. BMJ 2005;331(7523):986. No abstract available
Dressler LG et al. Comparison of HER2 status
by fluorescence in situ hybridization and
immunohistochemistry to predict benefit from
dose escalation of adjuvant doxorubicin-based
therapy in node-positive breast cancer patients. J Clin Oncol 2005;23(19):4287-97. Abstract
Dybdal N et al. Determination of HER2 gene
amplification by fluorescence in situ hybridization
and concordance with the clinical trials
immunohistochemical assay in women with
metastatic breast cancer evaluated for treatment
with trastuzumab. Breast Cancer Res Treat 2005;93(1):3-11. Abstract
Ellis CM et al. HER2 amplification status in
breast cancer: A comparison between immunohistochemical
staining and fluorescence in situ
hybridisation using manual and automated
quantitative image analysis scoring techniques. J Clin Pathol 2005;58(7):710-4. Abstract
Ewer MS et al. Reversibility of trastuzumabrelated
cardiotoxicity: New insights based on
clinical course and response to medical treatment. J Clin Oncol 2005;23(31):7820-6. Abstract
Gasparini G et al. Therapy of breast cancer with
molecular targeting agents. Ann Oncol 2005;16
Suppl 4:iv28-iv36. Abstract
Gong Y et al. Reliability of chromogenic in situ
hybridization for detecting HER-2 gene status
in breast cancer: Comparison with fluorescence
in situ hybridization and assessment
of interobserver reproducibility. Mod Pathol 2005;18(8):1015-21. Abstract
Hampton T. Monoclonal antibody therapies
shine in breast cancer clinical trials. JAMA 2005;293(24):2985-9. No abstract available
Hicks DG, Tubbs RR. Assessment of the HER2
status in breast cancer by fluorescence in situ
hybridization: A technical review with interpretive
guidelines. Hum Pathol 2005;36(3):250-61.
Abstract
Hobday TJ, Perez EA. Molecularly targeted
therapies for breast cancer. Cancer Control 2005;12(2):73-81. Abstract
Hortobagyi GN. Trastuzumab in the
treatment of breast cancer. N Engl J Med 2005;353(16):1734-6. No abstract available
Kounelis S et al. Evaluation of HER2 gene
status in breast cancer by chromogenic
in situ hybridization: Comparison with
immunohistochemistry. Anticancer Res 2005;25(2A):939-46. Abstract
Lan C et al. erb-b2 amplification by fluorescence
in situ hybridization in breast cancer specimens
read as 2+ in immunohistochemical analysis. Am J Clin Pathol 2005;124(1):97-102. Abstract
Leyland-Jones B et al. Pharmacokinetics, safety,
and efficacy of trastuzumab administered every
three weeks in combination with paclitaxel. J Clin Oncol 2003;21(21):3965-71. Abstract
Lottner C et al. Simultaneous detection of
HER2/neu gene amplification and protein
overexpression in paraffin-embedded breast
cancer. J Pathol 2005;205(5):577-84. Abstract
Ma Y et al. Polysomy 17 in HER-2/neu status
elaboration in breast cancer: Effect on daily
practice. Clin Cancer Res 2005;11(12):4393-9.
Abstract
Mass RD et al. Evaluation of clinical outcomes
according to HER2 detection by fluorescence
in situ hybridization in women with metastatic
breast cancer treated with trastuzumab. Clin
Breast Cancer 2005;6(3):240-6. Abstract
Nabholtz JM, Gligorov J. Docetaxel/trastuzumab
combination therapy for the treatment of breast
cancer. Expert Opin Pharmacother 2005;6(9):1555-
64. Abstract
Pegram MD et al. Rational combinations of
trastuzumab with chemotherapeutic drugs used
in the treatment of breast cancer. J Natl Cancer Inst 2004;96(10):739-49. Abstract
Peoples GE et al. Clinical trial results of a
HER2/neu (E75) vaccine to prevent recurrence
in high-risk breast cancer patients. J Clin Oncol 2005;23(30):7536-45. Abstract
Perez EA et al. Interim cardiac safety analysis
of NCCTG N9831 Intergroup adjuvant
trastuzumab trial. Proc ASCO 2005;Abstract 556.
Perez EA et al. NCCTG N9831: May 2005
update. Presentation. ASCO 2005;Abstract 556.
Perez EA et al. HER2 testing by local, central,
and reference laboratories in the NCCTG
N9831 Intergroup Adjuvant Trial. Proc ASCO 2004;Abstract 567.
Perez EA, Rodeheffer R. Clinical cardiac
tolerability of trastuzumab. J Clin Oncol 2004;22(2):322-9. Abstract
Piccart-Gebhart MJ. First results of the HERA
trial. Presentation. ASCO 2005. No abstract available
Piccart-Gebhart MJ et al. Trastuzumab after
adjuvant chemotherapy in HER2-positive breast
cancer. N Engl J Med 2005;353(16):1659-72.
Abstract
Press MF et al. Diagnostic evaluation of HER-2
as a molecular target: An assessment of accuracy
and reproducibility of laboratory testing in
large, prospective, randomized clinical trials. Clin Cancer Res 2005;11(18):6598-607. Abstract
Romond EH et al. Doxorubicin and
cyclophosphamide followed by paclitaxel with
or without trastuzumab as adjuvant therapy for
patients with HER-2 positive operable breast
cancer combined analysis of NSABP-B31/
NCCTG-N9831. Presentation. ASCO 2005. No
abstract available
Romond EH et al. Trastuzumab plus adjuvant
chemotherapy for operable HER2-positive
breast cancer. N Engl J Med 2005;353(16):1673-
84. Abstract
Rueckert S et al. A monoclonal antibody
as an effective therapeutic agent in breast
cancer: Trastuzumab. Expert Opin Biol Ther 2005;5(6):853-66. Abstract
Schmidt M et al. Long-term prognostic significance
of HER-2/neu in untreated node-negative
breast cancer depends on the method of testing. Breast Cancer Res 2005;7(2):R256-66. Abstract
Seidman A et al. Cardiac dysfunction in the
trastuzumab clinical trials experience. J Clin Oncol 2002;20(5):1215-21. Abstract
Spector N et al. The ErbB2 pathway in breast
cancer: Best approaches for maximum efficacy. Breast Cancer Res Treat 2004;Abstract MS3-4.
Spicer J et al. Adjuvant trastuzumab for
HER2-positive breast cancer. Lancet 2005;366(9486):634. No abstract available
Tan-Chiu E et al. Assessment of cardiac
dysfunction in a randomized trial comparing
doxorubicin and cyclophosphamide followed
by paclitaxel, with or without trastuzumab
as adjuvant therapy in node-positive, human
epidermal growth factor receptor 2-overexpressing
breast cancer: NSABP B-31. J Clin Oncol 2005;23(31):7811-9. Abstract
Tripathy D. Targeted therapies in breast cancer. Breast J 2005;11(Suppl 1):30-5. Abstract
Wakeling AE. Inhibitors of growth factor signalling. Endocr Relat Cancer 2005;12 Suppl 1:S183-7.
Abstract
Willems A et al. Antibody therapy for breast
cancer. Anticancer Res 2005;25(3A):1483-9.
Abstract
Yamaguchi Y et al. HER2-specific cytotoxic
activity of lymphokine-activated killer cells
in the presence of trastuzumab. Anticancer Res 2005;25(2A):827-32. Abstract
|